statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results...

Agenus to Provide First Quarter 2024 Financial Report and Corporate Update

The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity.

 Latest Ratings for AGEN...

Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom

Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced updated results from its Phase 1 clinical trial of BOT/BAL...

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Down 75%. Is Agenus Stock a Buy on the Dip...

Down 75%. Is Agenus Stock a Buy on the Dip?

Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approved a one-for-twenty reverse stock...

Agenus Announces Reverse Stock Split of Common Stock

Agenus Inc. ( NASDAQ:AGEN ) shareholders that were waiting for something to happen have been dealt a blow with a 25...

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

StockNews.com upgraded shares of Agenus (NASDAQ:AGEN  Free Report) from a sell rating to a hold rating in a research report released on Sunday morning. Several other analysts have also issued...

Agenus (NASDAQ:AGEN) Upgraded to Hold at StockNews.com

Agenus (NASDAQ:AGEN  Free Report) had its price objective cut by B. Riley from $6.00 to $5.00 in a report published on Monday morning, Benzinga reports. They currently have a buy rating on the...

Agenus (NASDAQ:AGEN) PT Lowered to $5.00 at B. Riley

Q4 2023 Agenus Inc Earnings Call and Corporate Update Transcript

Fast Track Designation for BOT/BAL in Colorectal Cancer and $25 Million Milestone Payment Highlight ProgressRelated Stocks: AGEN...

Agenus Inc (AGEN) Reports Full Year and Q4 2023 Financial Results, Advances in Oncology Pipeline

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Volume	12,438.00
52-Wk High	$42.60
52-Wk Low	$4.78

AGEN Agenus Inc

About

Feed

News

Sentiment

Earnings

Fundamentals